|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EDNRA |
Gene summary for EDNRA |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EDNRA | Gene ID | 1909 |
| Gene name | endothelin receptor type A | |
| Gene Alias | ET-A | |
| Cytomap | 4q31.22-q31.23 | |
| Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | P25101 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1909 | EDNRA | ATC12 | Human | Thyroid | ATC | 8.36e-14 | 6.11e-01 | 0.34 |
| 1909 | EDNRA | ATC13 | Human | Thyroid | ATC | 2.14e-70 | 2.03e+00 | 0.34 |
| 1909 | EDNRA | ATC4 | Human | Thyroid | ATC | 3.30e-22 | 7.77e-01 | 0.34 |
| 1909 | EDNRA | ATC5 | Human | Thyroid | ATC | 6.13e-85 | 2.15e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007048228 | Thyroid | ATC | response to oxygen levels | 193/6293 | 347/18723 | 1.83e-17 | 1.93e-15 | 193 |
| GO:003629328 | Thyroid | ATC | response to decreased oxygen levels | 177/6293 | 322/18723 | 1.81e-15 | 1.32e-13 | 177 |
| GO:000166628 | Thyroid | ATC | response to hypoxia | 169/6293 | 307/18723 | 6.58e-15 | 4.12e-13 | 169 |
| GO:000170126 | Thyroid | ATC | in utero embryonic development | 183/6293 | 367/18723 | 6.62e-11 | 2.11e-09 | 183 |
| GO:006056222 | Thyroid | ATC | epithelial tube morphogenesis | 156/6293 | 325/18723 | 4.48e-08 | 8.14e-07 | 156 |
| GO:004876221 | Thyroid | ATC | mesenchymal cell differentiation | 116/6293 | 236/18723 | 5.08e-07 | 7.30e-06 | 116 |
| GO:006048521 | Thyroid | ATC | mesenchyme development | 136/6293 | 291/18723 | 2.04e-06 | 2.43e-05 | 136 |
| GO:000176317 | Thyroid | ATC | morphogenesis of a branching structure | 96/6293 | 196/18723 | 5.68e-06 | 6.04e-05 | 96 |
| GO:006113815 | Thyroid | ATC | morphogenesis of a branching epithelium | 88/6293 | 182/18723 | 2.55e-05 | 2.20e-04 | 88 |
| GO:004886321 | Thyroid | ATC | stem cell differentiation | 97/6293 | 206/18723 | 3.88e-05 | 3.15e-04 | 97 |
| GO:00487545 | Thyroid | ATC | branching morphogenesis of an epithelial tube | 71/6293 | 151/18723 | 4.18e-04 | 2.50e-03 | 71 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | Breast | ADJ |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | Breast | DCIS |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | Breast | Healthy |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | Breast | Precancer |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | Cervix | ADJ |
| EDN3 | EDNRA | EDN3_EDNRA | EDN | Cervix | ADJ |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | Cervix | CC |
| EDN2 | EDNRA | EDN2_EDNRA | EDN | Cervix | CC |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | CRC | MSI-H |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | Endometrium | ADJ |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | Endometrium | AEH |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | Endometrium | EEC |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | Endometrium | Healthy |
| EDN3 | EDNRA | EDN3_EDNRA | EDN | Endometrium | Healthy |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | Esophagus | ESCC |
| EDN2 | EDNRA | EDN2_EDNRA | EDN | Esophagus | ESCC |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | HNSCC | ADJ |
| EDN3 | EDNRA | EDN3_EDNRA | EDN | HNSCC | ADJ |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | HNSCC | OSCC |
| EDN1 | EDNRA | EDN1_EDNRA | EDN | HNSCC | Precancer |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EDNRA | SNV | Missense_Mutation | rs139739379 | c.121C>T | p.Arg41Cys | p.R41C | P25101 | protein_coding | tolerated_low_confidence(0.09) | benign(0.118) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EDNRA | SNV | Missense_Mutation | rs751925818 | c.433C>T | p.Arg145Cys | p.R145C | P25101 | protein_coding | deleterious(0.01) | possibly_damaging(0.892) | TCGA-C8-A1HF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| EDNRA | insertion | In_Frame_Ins | novel | c.213_214insAGTAAA | p.Gln71_Gln72insSerLys | p.Q71_Q72insSK | P25101 | protein_coding | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| EDNRA | insertion | Nonsense_Mutation | novel | c.214_215insTCATTTTATGAATTT | p.Gln72delinsLeuIleLeuTerIleTer | p.Q72delinsLIL*I* | P25101 | protein_coding | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| EDNRA | deletion | Frame_Shift_Del | c.827delN | p.Leu277SerfsTer2 | p.L277Sfs*2 | P25101 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| EDNRA | SNV | Missense_Mutation | novel | c.872G>C | p.Arg291Thr | p.R291T | P25101 | protein_coding | deleterious(0.01) | probably_damaging(0.944) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| EDNRA | SNV | Missense_Mutation | c.1234N>G | p.Gln412Glu | p.Q412E | P25101 | protein_coding | tolerated(0.38) | benign(0) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| EDNRA | SNV | Missense_Mutation | c.703N>G | p.Gln235Glu | p.Q235E | P25101 | protein_coding | tolerated(1) | benign(0) | TCGA-A6-3808-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| EDNRA | SNV | Missense_Mutation | novel | c.680T>A | p.Val227Glu | p.V227E | P25101 | protein_coding | deleterious(0.01) | possibly_damaging(0.875) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| EDNRA | SNV | Missense_Mutation | c.469N>A | p.Leu157Ile | p.L157I | P25101 | protein_coding | tolerated(0.15) | possibly_damaging(0.53) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1909 | EDNRA | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | 178100518 | ZIBOTENTAN | |
| 1909 | EDNRA | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | CHEMBL1111 | AMBRISENTAN | |
| 1909 | EDNRA | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | SITAXSENTAN | SITAXENTAN | ||
| 1909 | EDNRA | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | SPI-1620 | IRL-1620 | ||
| 1909 | EDNRA | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135652579 | ||
| 1909 | EDNRA | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | CHEMBL957 | BOSENTAN | |
| 1909 | EDNRA | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | PD-145065 | |||
| 1909 | EDNRA | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | 135652048 | BQ-123 | |
| 1909 | EDNRA | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135651742 | ||
| 1909 | EDNRA | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | antagonist | CHEMBL2103873 | MACITENTAN |
| Page: 1 2 3 4 5 6 7 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |